First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony (Q28475794)

From Wikidata
Jump to navigation Jump to search
scientific article
edit
Language Label Description Also known as
English
First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony
scientific article

    Statements

    First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony (English)
    0 references
    Cesar Miranda-Verastegui
    0 references
    Gianfranco Tulliano
    0 references
    Theresa W Gyorkos
    0 references
    Wessmark Calderon
    0 references
    Elham Rahme
    0 references
    Brian Ward
    0 references
    Maria Cruz
    0 references
    Alejandro Llanos-Cuentas
    0 references
    Greg Matlashewski
    0 references
    28 July 2009
    0 references
    3
    0 references
    7
    0 references
    e491
    0 references

    Identifiers

     
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    edit